#md pharma consulting group

[sublimeobservationarcade]

A Terrible Indictment On American Doctors

The opioid crisis in America is a terrible indictment on American doctors. The fact that OxyContin was widely prescribed  as a safe cure for pain despite being an opioid is testament to the stupidity and gullibility of American doctors. The training and experience of medical practitioners should have indemnified them with a healthy scepticism for claims made by the pharmaceutical companies in this instance. Opioids have been known to be highly addictive for many decades and there have been no exceptions to this over the period.

https://youtu.be/lbyTDn__g44

American Doctors Must Doubt Drug Company Claims

Yes, the Sackler family, owners of Purdue Pharma, manipulated the FDA and falsified data around the safety of their opioid drug. The willingness of doctors, however, to believe in the sanctity of the commercially driven medical science edifice is naïve at best and expediently mercantile at worst. If doctors are so completely in the pocket of Big Pharma it is a very bad day for Americans in need of medical help. MDs need to have the objective strength to stand apart from the sales driven culture of the drug business. Doctors are really required to have doubt and a healthy scepticism in response to drug company claims. The overwhelming evidence of pharmaceutical corporations bribing doctors through lavish dinners, gifts, and holidays must make them bristle with suspicion.

Big Pharma Buying American MDs

The manipulation of the business of health by Big Pharma is considerable. Support groups around conditions and illnesses have been infiltrated by drug companies in the form of funding and sponsorship. This was clearly revealed in the inquiries into OxyContin and Purdue Pharma. National and community pain management organisations were bought by Purdue Pharma and the associated Sackler family companies via their money. Members of the FDA involved in the approval process found themselves moving on to well paid jobs at Purdue Pharma. Indeed, state attorneys in the justice system likewise were headhunted by Big Pharma. Oversight agencies do not work in the capitalist system because these inspectors are poached and bribed by the deep pockets of corporate America. Similarly, politicians pass legislation friendly to these corporations and later find themselves on their payroll upon leaving office as consultants. This makes the checks and balances within the system a weak joke in terms of their effectiveness in real terms. Government in America is bought and sold by big business. Money talks and Big Pharma is the loudest voice in the room. Capitalism does not serve democracy well and it does not serve health well either. If you have members of Congress spending their entire time worrying about being re-elected and it costs millions of dollars to do so, then you have a system that does not serve the people. Similarly, a health system, driven by pharmacology and the businesses making these drugs, is in the hands of profit driven masters. Doctors have become mere shadow puppets of their drug lords handing out a pill for every condition and situation. The over-prescribing of medication is endemic throughout America.

Giant pharmaceutical corporations are so economically powerful now that they dwarf governments around the globe. Covid only made these behemoths even more massive. Pfizer, Johnson & Johnson, Novartis, Roche and Sanofi all generate revenue in excess of $40 billion per year. The sales departments of these mega corporations have tentacles throughout the medical edifices around the world. Doctors and dispensing chemists are the influencers and retailers for this simply gargantuan industry. Doctors hold a special place within our society. The white lab coat is similarly a symbol of the presumed purity of the healer at the heart of the medical system. In an emotive sense, people do not instinctively associate healing with the money making principle. When someone gets sick they, often, panic and just want a cure. This is exploited by a health system driven by capitalism, where the importance of making money and delivering dividends to shareholders drives the cart. In the current opioid crisis in America there were a number of doctors who ruthlessly exploited, for financial benefit, the addictive qualities of OxyContin. This is a terrible indictment on American doctors in itself, but that many more MDs claimed to be hoodwinked by the FDA and supporting scientific material provided by Purdue Pharma is probably worse. It attests to a dumbing down and lowering of standards within the American medical fraternity. It tells us that the sales driven culture of Big Pharma is supported by American doctors. Medicine in the US is predominantly all about the dollars and less about patent welfare. ©WordsForWeb Read the full article

[mdpharmaconsultinggroup]

We, @mdpharmaconsultinggroup, the international healthcare consultancy expert, were privileged and honored to be chosen as a reliable partner with international organizations and governments to improve healthcare systems. Because we speak global healthcare language, and we have the know how, we will be sharing in development, revision, and implementation of the first National Egyptian Clinical Guidelines

نحن ، مجموعة إم دي فارما الاستشارية ، الخبير الدولي في استشارات الرعاية الصحية ، تشرفنا وفخرنا باختيارنا كشريك موثوق به مع المنظمات الدولية والحكومات لتحسين أنظمة الرعاية الصحية. ونظرًا لأننا نتحدث لغة الرعاية الصحية العالمية ، ولدينا المعرفة الكافية ، فسوف نشارك في تطوير ومراجعة وتنفيذ أول إرشادات طبية مصرية وطنية

Bassem Toeama

#clinicalguidance #clinicaltrial #medicalwriting #pharmacovigilance #medicalpublications #digitalhealth #CME

[didanawisgi]

“History is highlighted by turning points, moments of brilliance in the journey of humanity, episodes that changed civilization. These junctures often took place at times of great tragedy, during wars, famines, plagues, and revolution. Because at precisely those times, when the worst of human depravity became evident, we also witnessed the emergence of some of our greatest humanitarians, those who withstood opposition with grace and wisdom.

As steel is forged in a blast furnace, the best in humanity can only arise out of its cruelest chapters. Oskar Schindler, a Nazi, gave away all his wealth to safeguard vulnerable Jewish people out of harm’s way, away from the gas chambers. Oskar devoted his life at significant personal risk to saving others less fortunate; this is perhaps the fundamental principle of humanity.

Mohandas Gandhi raised a family as a successful lawyer in South Africa yet chose to return to India to stop genocide. He traded a life of comfort for one of fasting, nonviolent protests, and personal risk. An assassin's bullet took his life in 1948, but not before he had spent 78 years on the planet and changed it forever. He is revered by many as the Father of India. His nonviolent protests to further social change inspired others to do the same, like Martin Luther King Jr, Robert Kennedy, and Nelson Mandela.

Nelson Mandela paid his price of tribulation with 27 years in a prison cell, one without a bed or plumbing. He spent his days breaking rocks and his free time writing. His manuscripts were scrutinized, restricted, censored, or destroyed. Nonetheless, he smuggled out a 500-page autobiography in 1976 and led a protest movement for prison rights.

This expanded into the anti-apartheid movement in South Africa. Out of Mandela's great suffering arose the principle of racial equality for South Africa, where he would ultimately be elected its first president. He remains affectionately known today as Madiba and is widely regarded as the Father of the Nation. He won the Nobel Peace Prize in 1993 for his nonviolent protests that proved victorious in ending the apartheid regime.

Dr. Tess Lawrie is a world-class researcher and consultant to the World Health Organization. Her biggest clients happen to be those who are involved in the suppression of repurposed drugs. She has decided to speak out in protest against the current medical establishment at considerable personal risk.

She co-founded the BIRD panel, an international group of experts dedicated to the transparent and accurate scientific research of Ivermectin. On April 24, 2021, she convened the International Ivermectin for COVID Conference, the first such symposium in the world held to focus on Ivermectin to prevent and treat COVID-19.

During the conference, she delivered a monumental closing address, one that will be recorded in the annals of medical history.

"They who design the trials and control the data also control the outcome. So, this system of industry-led trials needs to be put to an end. Data from ongoing and future trials of novel COVID treatments must be independently controlled and analyzed. Anything less than total transparency cannot be trusted."

Dr. Lawrie called for reform of the method used to analyze scientific evidence.

She reported, "The story of Ivermectin has highlighted that we are at a remarkable juncture in medical history. The tools that we use to heal and our connection with our patients are being systematically undermined by relentless disinformation stemming from corporate greed. The story of Ivermectin shows that we as a public have misplaced our trust in the authorities and have underestimated the extent to which money and power corrupts.

Had Ivermectin being employed in 2020 when medical colleagues around the world first alerted the authorities to its efficacy, millions of lives could have been saved, and the pandemic with all its associated suffering and loss brought to a rapid and timely end."

Dr. Lawrie called out the corruption of modern medicine by Big Pharma and other interests.

She went on, "Since then, hundreds of millions of people have been involved in the largest medical experiment in human history. Mass vaccination was an unproven novel therapy. Hundreds of billions will be made by Big Pharma and paid for by the public. With politicians and other nonmedical individuals dictating to us what we are allowed to prescribe to the ill, we as doctors, have been put in a position such that our ability to uphold the Hippocratic oath is under attack.

At this fateful juncture, we must therefore choose, will we continue to be held ransom by corrupt organizations, health authorities, Big Pharma, and billionaire sociopaths, or will we do our moral and professional duty to do no harm and always do the best for those in our care? The latter includes urgently reaching out to colleagues around the world to discuss which of our tried and tested safe older medicines can be used against COVID."

Finally, Dr. Lawrie suggested that physicians form a new World Health Organization that represents the interests of the people, not corporations and billionaires, a people-centered organization.

"Never before has our role as doctors been so important because never before have we become complicit in causing so much harm."

Dr. Albert Schweitzer would be proud. A Nobel laureate from 1952, Dr. Schweitzer won the Nobel Prize not for his work as a renowned medical missionary physician, but "for his altruism, reverence for life, and tireless humanitarian work which has helped make the idea of brotherhood between men and nations a living one."

While Mandela and King fought for equality in human rights, Dr. Schweitzer is most remembered for his principle of the ethic of "reverence for life."  

Schweitzer wrote, "Ethics is nothing other than reverence for life. Reverence for life affords me my fundamental principle of morality, namely, that good consists of maintaining, assisting, and enhancing life, and to destroy, harm or hinder life is evil."

Dr. Tess Lawrie knows that scientifically, Ivermectin saves lives. But moreover, she knows beyond any doubt that corruption has prevented Ivermectin from saving millions, caused untold suffering and horror, and a human economic toll of unimaginable proportions.

Out of this Pandemic have risen the true healers, those physicians who will be forever revered for risking their careers to save lives. When they could have remained silent and allowed the pandemic to take its course without rocking the boat, they chose to act.

Dr. George Fareed, Dr. Harvey Risch, and Dr. Peter McCullough traveled to the US Capitol and addressed the US Senate on November 19, 2020 and pleaded for the FDA and NIH to institute early outpatient treatment. They warned of the surge in deaths that would come. No answer. However, now during the current deadly second surge in India, on April 22, the Indian Council of Medical Research has just adopted Ivermectin and Budesonide for early outpatient therapy.

So why couldn’t the US have done the same and heed the advice of Fareed and others, and with the stroke of a pen in November accord Ivermectin Emergency Use Authorization? Fully 300,000 lives could have been saved.

These physicians are the pandemic humanitarians; to Dr. George Fareed, who stood up to Dr. Anthony Fauci; to Dr. Brian Tyson, who borrowed $250,000  in a personal loan to save the Imperial Valley; and to Dr. Harvey Risch, who risked his professorship at Yale to speak out; to Dr. Peter McCullough of Texas, who authored the first study on early outpatient treatment; to Dr. Pierre Kory, who put his career on the line, to Dr. Tess Lawrie, physician, humanitarian, and reformer, who is leading the path to victory over the pandemic, a beacon of hope for human rights and the conscience of medicine.”

Signed, 

Justus R. Hope, MD

[healthcareandwellness-blog]

Hypomethylating Agents Market: Introduction

Hypomethylating agents act as an essential tool in the treatment of health disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia. These are not the only available treatment options, but their use can further be integrated and optimized in a sequential treatment strategy. The hypomethylating agents are also called as DNA methyltransferase inhibitors. These have allowed the treatment of frail and higher-risk elderly patients.

Request for a sample copy of this report @ https://www.insightsandreports.com/request-sample/188

Market Dynamics

Increasing MDS cases among the population within the age group of above 50 years is one of the major reasons driving the hypomethylating agents’ market significantly. According to the American Cancer Society, the number of people who are diagnosed with MDS in the U.S. every year is unknown, but according to a study conducted by this society, around 10,000 cases are being registered in the U.S. alone, while some other estimates are much higher.

This health disorder is highly uncommon before the age of 50, and moreover, the health risks associated with disease gradually increases along with the person’s age. In the U.S., the new cases diagnosed each year are rising, as the average person’s age among the U.S. population is increasing. As the chances of disease outbreak are higher for this age group, the demand for hypomethylating agents is also predicted to grow over the forecast period.

Moreover, growing allogeneic stem cell transplants along with higher intensity approaches for the treatment of MDS, is expected to yield higher response rates and can also control the disease’s negative impact for longer times. These type of treatment facilities are increasing across the world, which will give an additional boost to the growth of hypomethylating agents market.

Hypomethylating agents market is expected to restrain, owing to the unmet need for sound treatment options among the patients. Moreover, the response rates of these agents for the control of disease’s impact is also very low, according to the National Institute of Health and American Cancer Society. These factors are expected to restrain the hypomethylating agents market significantly over the forecast period.

By Type of Treatment

By type of treatment, the hypomethylating agents market has been segmented into acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). Hypomethylating agents market for myelodysplastic syndromes is expected to have the dominant market share over the forecast period. Increasing new cases, coupled with the developing treatment options for this disorder are expected to attribute the prime share of hypomethylating agents market for myelodysplastic syndromes.

By Gender

Based on gender, the global hypomethylating agents market has been segmented into male and female. Over the forecast period, the use of hypomethylating agents for male population is projected to dominate the product use among female population. This is majorly due to the higher disease incidence chances among men, compared to women. According to the estimates by the American Cancer Society, in 2017, around 19,520 new cases of AML have been identified in the U.S. alone, out of which more than 10,670 deaths are observed, which are mostly among adults, especially among men.

By Region

North America hypomethylating agents market is expected to have the prime share in the global market over the projected period. It is majorly attributed by the increasing cases, and growing treatment facilities, along with the presence of major research organizations (NIH, ACS), and pharmaceutical companies, which are currently striving towards the research and development of new drugs to treat MDS, and AML.

Asia Pacific hypomethylating agents market is expected to witness a higher growth over the forecast period, majorly owing to the presence of key pharmaceutical companies. Manufacturing companies in this region are majorly focusing on the development of these agents, owing to the increasing cases of MDS and AML. Moreover, the governing bodies of several countries in this region are majorly focusing on the development of healthcare industry, which will provide lucrative opportunities for the hypomethylating agents market to grow over the forecast period.

Competitive Landscape

Some of the prominent players in the global hypomethylating agents market include Pfizer, Blue Point Laboratories, Actavis Pharma Company, Dr. Reddy’s Laboratories, Celgene, Cipla Limited, Otsuka Pharmaceuticals, Astex Pharmaceuticals, etc. among others.

Some key pharmaceutical companies such as Cipla Limited and Otsuka Pharmaceuticals are working constantly to get FDA approvals of the drugs developed. For instance, Cipla Limited received a final approval from the U.S. FDA for its generic drug Dacogen in November 2017.

Also, many prominent players are trying to obtain the rights from generic drug manufacturers to expand their geographic horizon in the global hypomethylating agents market. For instance, in March 2014, Otsuka Pharmaceuticals acquired rights from EISAI Inc. for the development and marketing of Dacogen in U.S., Canada, and Japan markets. 

For more information about this report @ https://www.insightsandreports.com/industry-reports/hypomethylating-agents-market

About Us:

Insights and Reports is a research and consulting group assisting the clients with 360-degree insights with real time qualitative and quantitative information. The Insights and Reports team is valued for continuous client-oriented services. Our data scientists monitor the markets pertaining to their expertise on a daily basis with the help of 150+ analysts to back them with accurate market studies.

 Contact Us:

Mr. Saby

Insights And Reports

2201 Cooperative Way #600,

Herndon, VA 20171, USA.

Tel: +1 703 574 4447

Email: sales@insightsandreports.com

[variationsolution]

Variation Compusolution

Building organizations through improving careers is perhaps the most recommended way to hunt for a talent in the jobs industry. As a preferred talent acquisition partner for multinationals, Variation Compusolution is the most trusted recruitment consultants for leading businesses.

In more than two decades since our launch, we have received immense love and support for being the pioneer of organized recruitment and a market leader with unparalleled network of clients and job seekers. Our founder and CEO, Mandeep Kaur Ghotra, has always believed in helping companies grow, with the right talent. With a deep understanding and a rich experience in talent acquisition, Mandeep has bagged many awards in a Leadership role, few being…

-          Excellence award from Vikram Oberoi, MD, The Oberoi Group.

-          Business Leadership award at the India International Business Summit, New Delhi.

-          Best performer award, Bill Marriott.

-          Consistent performer award from Infosys, Chandigarh.

Her experience in talent acquisition taught Mandeep that not all industries are the same, which is why their needs for filling a job position will be different. And that is where the creative process for finding the best solution for problems in hiring began. As a firm, Variation Compusolution provides customized recruitment solutions for every need, pertaining to different industries it serves, few of them being Aviation and Aerospace, Chemical, Mining and Metals, Oil and Refinery, Pharma and Research, and Hospital and Healthcare.

With a skilled team of recruiting consultants, Variation Compusolution follows a very streamlined process of staffing, to provide the business, institution or a recruitment firm with the best talent. We understand that as the employer, a firm also puts in a lot of effort, time and money to train and induct a new employee as a part of the team. That is why our customized solutions are not only aimed at staff hunting, but also sustaining the satisfaction of our clients through our service and result-delivery timeline.    

[amshrihari]

U.S. MEIBOMIAN GLAND DYSFUNCTION MARKET ANALYSIS

U.S. Meibomian Gland Dysfunction Market, By Drug Type (Cyclosporine, Omega-3 supplements, Antibacterial Eye Drops, Steroids, AZR MD 001, TP 03, NOV03 (Novatears), and HY02–Minocycline), By Route of Administration (Oral and Topical), and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2030

PRESS RELEASE:  U.S. Meibomian Gland Dysfunction Market

Request free sample copy                                                       Download PDF

Meibomian gland dysfunction is a cause of dry eye syndrome (DES), also known as keratisis sicca and keratoconjunctivitis sicca. Patients with DES suffer damage to the ocular surface, instability in the tear film, and visual disturbance. Tear film covers the ocular surface, which is made up of three intertwined layers, a superficial lipid layer, produced by meibomian glands, which assists in reducing tear evaporation and uniform tear spreading, middle thick aqueous layer produced from lacrimal glands, and the innermost hydrophilic mucin layer produced from goblet cells of conjunctiva and epithelium of ocular surface.

The U.S. meibomian gland dysfunction market is estimated to be valued at US$ 1,976.6 million in 2020 and is expected to exhibit a CAGR of 15.4% during the forecast period (2020-2030).

Figure 1. U.S. Meibomian Gland Dysfunction Market Share (%) by Drug Type, 2020

 The increasing prevalence of meibomian gland dysfunction syndrome is expected to drive the market growth during the forecast period.

According to the Fellow of the American College of Surgeons, meibomian gland disease (also referred as evaporative dry eye), is one of the most common causes of dry eyes across the globe. An estimated 50 to 70% of the elderly population has some degree of dry eye and nearly 70% of dry eye involves at least some degree of meibomian gland disease.

According to a study published by the American Optometric Association in 2017, more than 16 million Americans, including twice as many women than men, were suffering from dry eye disease, and out of them around 70% of patients had meibomian gland disease.

Furthermore, certain medications such as antihistamines, antidepressants, decongestants, and blood pressure medications can reduce tear production leading to dry eye symptoms which cause meibomian gland dysfunction.

Figure 2. U.S. Meibomian Gland Dysfunction Market Share (%), by Distribution Channel, 2020

The increasing excess usage of computers and mobile screens is expected to increase the incidence of meibomian gland dysfunction over the period of time

People who frequently use computers or video screens are at high risk of developing meibomian gland dysfunction, as using screens for a long duration can lead to reduced blinking and tears production. Digital device usage has increased significantly in recent years among all age groups, due to extensive use for social and professional purposes.

Blue light emitted by digital screens can lead to symptoms of dry eyes which cause meibomian gland dysfunction. Exposure to blue light (range of 400–500 nm) can be harmful to the retina. Longer duration and less intense light exposure can also induce photochemical damage in the eyes.

Furthermore, lack of sleep and excessive stress can play a crucial role in the onset of dry eye syndrome due to oily tear gland dysfunction.

According to the Centers for Disease Control and Prevention’s 2017 report, over 40 million American workers get less than six hours of sleep per night.

U.S. Meibomian Gland Dysfunction Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries around the globe with the World Health Organization declaring it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 6.61 million infected individuals in the U.S. as of 16 September 2020. COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. In the U.S., according to the latest update of Economic Times, there has been a plunge in consumer spending as people stayed home and avoided shopping, traveling or gathering in crowds and caused the economy to sink at an estimated annual rate of 32% in the April-June 2020 quarter.

Furthermore, players operating in the U.S. meibomian gland dysfunction market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials for manufacturing drug formulations due to irregularities in transportation facility. Moreover, distributors of drug products are experiencing irregular demand from the retailers.

U.S. Meibomian Gland Dysfunction Market: Restraints

Potential side effects of drugs, such as steroids, used in the treatment of meibomian gland dysfunction syndrome have a wide range of side effects on the body of the patient who is continuously taking more than the prescribed dose of steroids for a longer period of time. This is expected to restrain the market growth during the forecast period.

Difficulty in disease diagnosis is also expected to hamper the market growth during the forecast period. Since, there is no single test for the diagnosis of meibomian gland dysfunction, clinicians use slit lamp findings such as lid observations, tear meniscus height, and corneal staining for assessment of this disease. Many other tests such as tear film osmolarity, inflammatory markers, and conjunctival staining are not widely used as these are expensive and take longer time. Moreover, there is a discrepancy among signs and symptoms and results of various tests for meibomian gland dysfunction as they do not correlate with each other. This variability can create confusion among patients and healthcare providers about the best course of treatment.

Key Players

Major players operating in the U.S. meibomian gland dysfunction market are Pfizer, Inc., AbbVie Inc., Johnson and Johnson Vision Care Inc., Bausch Health Companies Inc., Novartis AG, Santen Pharmaceutical Co., Ltd., I-MED Pharma Inc., OASIS Medical, Sentiss Pharma Pvt. Ltd., RegeneRx, and Akorn, Inc.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

 Contact Us:

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email: sales@coherentmarketinsights.com

[sublimeobservationarcade]

A Terrible Indictment On American Doctors

The opioid crisis in America is a terrible indictment on American doctors. The fact that OxyContin was widely prescribed  as a safe cure for pain despite being an opioid is testament to the stupidity and gullibility of American doctors. The training and experience of medical practitioners should have indemnified them with a healthy scepticism for claims made by the pharmaceutical companies in this instance. Opioids have been known to be highly addictive for many decades and there have been no exceptions to this over the period.

American Doctors Must Doubt Drug Company Claims

Yes, the Sackler family, owners of Purdue Pharma, manipulated the FDA and falsified data around the safety of their opioid drug. The willingness of doctors, however, to believe in the sanctity of the commercially driven medical science edifice is naïve at best and expediently mercantile at worst. If doctors are so completely in the pocket of Big Pharma it is a very bad day for Americans in need of medical help. MDs need to have the objective strength to stand apart from the sales driven culture of the drug business. Doctors are really required to have doubt and a healthy scepticism in response to drug company claims. The overwhelming evidence of pharmaceutical corporations bribing doctors through lavish dinners, gifts, and holidays must make them bristle with suspicion.

Big Pharma Buying American MDs

The manipulation of the business of health by Big Pharma is considerable. Support groups around conditions and illnesses have been infiltrated by drug companies in the form of funding and sponsorship. This was clearly revealed in the inquiries into OxyContin and Purdue Pharma. National and community pain management organisations were bought by Purdue Pharma and the associated Sacker family companies via their money. Members of the FDA involved in the approval process found themselves moving on to well paid jobs at Purdue Pharma. Indeed, state attorneys in the justice system likewise were headhunted by Big Pharma. Oversight agencies do not work in the capitalist system because these inspectors are poached and bribed by the deep pockets of corporate America. Similarly, politicians pass legislation friendly to these corporations and later find themselves on their payroll upon leaving office as consultants. This makes the checks and balances within the system a weak joke in terms of their effectiveness in real terms. Government in America is bought and sold by big business. Money talks and Big Pharma is the loudest voice in the room. Capitalism does not serve democracy well and it does not serve health well either. If you have members of Congress spending their entire time worrying about being re-elected and it costs millions of dollars to do so, then you have a system that does not serve the people. Similarly, a health system, driven by pharmacology and the businesses making these drugs, is in the hands of profit driven masters. Doctors have become mere shadow puppets of their drug lords handing out a pill for every condition and situation. The over-prescribing of medication is endemic throughout America.

Giant pharmaceutical corporations are so economically powerful now that they dwarf governments around the globe. Covid only made these behemoths even more massive. Pfizer, Johnson & Johnson, Novartis, Roche and Sanofi all generate revenue in excess of $40 billion per year. The sales departments of these mega corporations have tentacles throughout the medical edifices around the world. Doctors and dispensing chemists are the influencers and retailers for this simply gargantuan industry. Doctors hold a special place within our society. The white lab coat is similarly a symbol of the presumed purity of the healer at the heart of the medical system. In an emotive sense, people do not instinctively associate healing with the money making principle. When someone gets sick they, often, panic and just want a cure. This is exploited by a health system driven by capitalism, where the importance of making money and delivering dividends to shareholders drives the cart. In the current opioid crisis in America there were a number of doctors who ruthlessly exploited, for financial benefit, the addictive qualities of OxyContin. This is a terrible indictment on American doctors in itself, but that many more MDs claimed to be hoodwinked by the FDA and supporting scientific material provided by Purdue Pharma is probably worse. It attests to a dumbing down and lowering of standards within the American medical fraternity. It tells us that the sales driven culture of Big Pharma is supported by American doctors. Medicine in the US is predominantly all about the dollars and less about patent welfare. ©WordsForWeb Read the full article

[mdpharmaconsultinggroup]

EdgePlus Inc. Registration is NOW open for 2023 PEBC & LMCC & CNPE:F/AA Canadian equivalency board exams for Pharmacists, Physicians & Nurses. Ask for you promo code "SUCCESS23" - valid only until December 31st (289) 242-9199

- PEBC OSCE "ULTIMA"+ 2 mock exams: https://lnkd.in/eqvTNX2d

- PEBC MCQ revision/Q&A bank & mock "https://lnkd.in/eJwNX5xp

- PEBC EE Premier + mock exam: https://lnkd.in/euZ3cySY

- LMCC: QE-1 + mock exam: https://lnkd.in/g9Tkir7K

- CNPE:F/AA + mock exam https://lnkd.in/eT34yxST

#pharmaceuticals #pharmacists #pebcexams #pebcexam #pharma #canada🇨🇦 #boardexam #gulf #egypt #unitedarabemirates #saudi #jordon #qatar #lebanon #oman #kuwait

[sknews7]

Alter Pharma Group Adopts Movilitas.Cloud to Ensure Safer Goods and EU FMD Compliance Throughout the Product Path and Changes in Packaging

COLUMBIA, Md., Sept. 16, 2020 /PRNewswire/ — Movilitas introduced that the Alter Pharma Group, a pharmaceutical group lively within the distribution of pharmaceutical merchandise to pharmacies, wholesalers, hospitals and retirement properties and within the growth and licensing of generic medication, adopted its Movilitas.Cloud software program as a service resolution to satisfy the many necessities within the (re)packaging course of which might be specified below the EU FMD regulation, whereas additionally benefiting from improved operational efficiencies all through the product path and modifications in packaging.               

Underneath the EU FMD directive, repackagers and parallel distributors have distinctive tasks. Their medicinal product is commonly purchased from regulated wholesalers after which drugs authenticity and product serial numbers should be verified and managed from geographically separated processing vegetation by means of the purpose of distribution.

“By leveraging Movilitas.Cloud expertise, we now have a state-of-the-art system that gives transparency and ensures the integrity of our merchandise as they transfer throughout the provision chain,” mentioned Stijn Vlaminck, IT Supervisor of the Alter Pharma Group.  “The answer supplies a single system to handle and observe every pack with a purpose to stay compliant with EU FMD laws and ship on the very best normal of high quality and security.”

Movilitas.Cloud provides a set of providers to keep up product integrity throughout modifications in packaging:

Helps the whole receiving and verification technique of unique medicines 

Sends automated decommissioning requests containing all serial numbers grouped into SSCCs

Sends commissioning requests of the repacked merchandise

Manages serial numbers between EU-Hub by means of QA performance

Helps handbook, semi-automatic and automated processes

“We’re pioneering an environment friendly means of managing the reporting of serial numbers in the course of the repackaging course of,” mentioned Marc Blekkink, international head of enterprise growth for Movilitas.Cloud. “We’re dedicated to delivering IoT options that allow repackagers and parallel importers to ship protected medicinal merchandise whereas remaining compliant.”

To be taught extra about Movilitas.Cloud for repackagers and parallel importers, please go to: https://www.movilitas.com/solutions/movilitas-cloud/repacker-eu-fmd-application/

Concerning the Alter Pharma Group

The Alter Pharma Group is a Belgian group of pharmaceutical corporations with headquarters in Anderlecht (Belgium) and places of work in Eire and the USA. Using in whole over 125 staff, the Group distributes a variety of pharmaceutical merchandise to pharmacies, wholesalers, hospitals and retirement properties. On the identical time, Alter Pharma is a worldwide participant on the generics market, with round 15 molecules on the European and US market and a completely stocked pipeline of area of interest, complicated and added worth merchandise.

To be taught extra in regards to the Alter Pharma Group, please go to: www.alterpharmagroup.be.

About Movilitas

Movilitas is a expertise chief delivering the following technology of options and consulting providers throughout industries to advance sensible provide chain ecosystems. We’re acknowledged as a trusted SAP companion for digital provide chain transformation. Via providers, comparable to Movilitas.Cloud, or accelerators for SAP options, our purchasers keep compliance and unlock information to comprehend better efficiencies. For extra info, go to movilitas.com.

SOURCE Movilitas

Associated Hyperlinks

https://www.movilitas.com

Source link

from WordPress https://ift.tt/3c8zqzl via IFTTT

[mariebenz]

Atopic Dermatitis - Eczema: Jakafi® (ruxolitinib) Found to Reduce Itch and Improve Quality of Life

MedicalResearch.com Interview with:

Dr. Kim Brian S. Kim, MD, MTR, FAAD Associate Professor of Medicine (Dermatology) Co-Director, Center for the Study of Itch and Sensory Disorders Division of Dermatology, Department of Medicine Washington University School of Medicine St. Louis, MO  MedicalResearch.com: What is the background for this study? What are the main findings? Response: Itch is the central and most debilitating symptom of atopic dermatitis. However, surprisingly, measuring itch or quality of life in clinical trials is not often a primary endpoint. Therefore, this study focuses in very detailed fashion on how ruxolitinib cream improves pruritus in a clinically meaningful way and its ultimate impact on quality of life. What patients want to know at the end of the day is how much will this drug change my life?  Not, whether it statistically beat out a placebo group. Indeed, what this study shows is that ruxolitinib cream has a major impact on itch in a meaningful way that is also tied to improvements in quality of life. MedicalResearch.com: What should readers take away from your report? Response: The key takeaways are the following: 1) Ruxolitinib cream has very rapid and potent anti-itch effects in atopic dermatitis, 2) The improvements in itch associated with treatment are clinically meaningful, and 3) The improvement in itch is strongly associated with improvement in quality of life. Overall, this means that patients who suffer disproportionately from itch associated with their eczema, can expect to see life-changing effects from this future treatment.  MedicalResearch.com: What recommendations do you have for future research as a result of this work?  Response: An interesting area of future research would be to understand whether ruxolitinib’s effect is due to its inhibition of JAKs in neurons versus inflammatory cells. A basic assumption in the field is that JAK inhibitors work via their effects on immune cells directly, however, we believe that the tremendous effect on itch is due to the neuromodulatory properties of the drug. However, this remains to be more directly demonstrated in humans. MedicalResearch.com: Is there anything else you would like to add? Response: I have worked as a consultant for Incyte and multiple other companies that make JAK inhibitors like AbbVie, Pfizer, and LEO Pharma. I also have a patent pending for the application of JAK inhibitors for pruritus. Citation: Effects of ruxolitinib cream on pruritus and quality of life in adult patients with atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled studyJournal of the American Academy of Dermatology, Volume 81, Issue 4, AB198 https://www.jaad.org/article/S0190-9622(19)31730-X/fulltext The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.   Read the full article

[austinwholeliving]

Workplace Wellness Fails for Two Reasons

A recent clinical study is making the rounds this spring about the lack of short term evidence workplace wellness contributes to positive economic outcomes. Instead of damaging workplace wellness, this only proves my point that we can’t focus on ROI when it comes to workplace wellness in the way we focus on so many other company-driven initiatives. There are many reasons for this, but as you can see below, the researchers responsible for this data point out that it’s the short-term results which don’t hold a lot of evidence for us. There’s yet to be a thorough long-term (10 years or more, I’d argue) study showing the affect of long-term cultural changes towards a healthier workplace and there are two big reasons why. 

Among employees of a large US warehouse retail company, a workplace wellness program resulted in significantly greater rates of some positive self-reported health behaviors among those exposed compared with employees who were not exposed, but there were no significant differences in clinical measures of health, health care spending and utilization, and employment outcomes after 18 months. Although limited by incomplete data on some outcomes, these findings may temper expectations about the financial return on investment that wellness programs can deliver in the short term. 

-Randomized Clinical Trial, Dr. Zirui Song, MD, PhD & Dr. Katherine Baicker, PhD

As a corporate wellness consultant, I help companies build healthier, happier places to work. But I didn’t start there. I’ve had a long history helping organizations design and manage their employee benefit programs. It’s from this complex insurance world I began to really view culture as a vital organ to the company’s life cycle; not only in terms of healthy, happy employees, but also the organization’s longevity and financial success. I learned employers could offer up the best insurance plans money could buy--often spending hundreds of thousands each year on insurance programs--and employees would still have very costly lifestyle diseases that often stem from chronic, unchecked stress reactions, such as heart disease and autoimmune disorders. Human beings aren’t meant to feel like stressed-out hamsters and I’ve come to believe that we all have the potential to thrive; a big chunk of how we thrive is to take care of ourselves in all aspects of our well-being and to profoundly connect with those around us.

To thrive requires we change our current paradigm. It requires we throw out what we know about corporate wellness programs and build a fresh foundation. For the past 30 years, workplace wellness has largely failed for two big reasons: Purpose and Approach. We’ve embarked on workplace wellness with a purpose to lower the ever-rising tide of healthcare costs; we were promised that by implementing wellness programs, our insurance premiums would go down and that’s just not the case for most employers in the general market (let’s exclude the giant self-funded companies for now). It’s not the case, because insurance premiums are affected by a multitude of nation-wide components, linked to Big Pharma, costly and redundant testing by providers in a non-coordinated fashion, expensive and sometimes unnecessary procedures, private hospital systems, out of network expenses, and humans living longer (cool though, right?). You can have a healthy population of 200 employees with 1 heart transplant and BOOM, there go your healthcare premiums for the next 12 to 18 months.  

The second piece of the failure, approach, has to do with employees feeling like this is being done to them, rather than for them. Forced bio-metric screens, penalties on healthcare charges, boring group activities, and wellness “programs” slapped together without taking into account the industry, population type, and current workplace culture are some of the reasons employees are over the current style of workplace wellness. I’m not suggesting employers spend a lot of money just to make their employees feel warm and fuzzy. Remember, changing your culture has the power to affect your bottom line. But the pathway to that is more challenging to measure. It’s not a cash based measurement; it’s more about recruitment, retention, productivity, less sick days, and all from happier, healthier employees who want to show up and get the job done well.  Employees that feel empowered to thrive both professionally and personally. 

The “Millennial Effect”

I sat through a potential wellness client meeting last year where “millennials” was used pejoratively (with eye rolls included) to describe a workforce expecting “fluff and nonsense” related to culture and wellness. There are now over 70,000,000 Millennials and guess what? We’ve been told from day one of our adult lives that Social Security is about to run out, pensions are dead, work security is non-existent, we have an average of $30,000 in student loan debt to repay, and we can expect to work well past the age of 65. So YES, we’re expecting more from our workplaces because we recognize the cost of spending the majority of our lives working for our paychecks. 

The tide is changing, but it’s not an “us vs. them” reality. We’re all in this together and shouldn’t we all participate in efforts that contribute to a more positive place to work? Sadly, we can’t expect healthcare costs to go down anytime soon. We can certainly make efforts to mitigate those costs, but until major evolution happens on that front, it’s still worth exploring how we can nurture our workplace cultures to benefit our total well-being, as humans and organizations. 

[syrtissolutions]

GOVERNOR NEWSOM'S EXECUTIVE ORDER: MEDI-CAL TO NEGOTIATE PRESCRIPTION DRUG PRICES

California's newly appointed governor; Gavin Newsom (D) has just recently taken a legislative measure to address skyrocketing drug prices. Soon after he was sworn in last week, Newsom authorized an executive order making the state responsible for negotiating drug prices directly with pharmaceutical drug companies. Furthermore, the governor is pursuing increased funding for Medi-Cal and a state-level individual mandate.

The order outlines a singular purchasing model which intends to achieve improved drug pricing for the state's Medicaid program. Newsom is attempting to making use of the purchasing power that comes along with a Medicaid population of over 13 million and growing. In addition, there is very little doubt that carrying out the order will have ramifications with California's relationship with big pharma. Under the order, California will develop a list of drugs to be purchased in bulk as well as target specific medications for negotiation. It would also enable private payers to participate in the public system and negotiate prices.

Advocates of the initiative view it as a chance to not only decrease costs locally but also at the federal level. Jack Hoadley, an analyst at Georgetown University's Health Policy Institute, believes that the order could promote the use of high priced pharmaceuticals and make them more common.

Hoadley stated, "States like California could bring a lot of leverage to a sole-source drug that is priced very high."

Friso van Reesema specializes in Medicaid pharma at Cipher Health and sees Newsom's executive order as an "interesting move that shows that states are diving deeper into their budgets to identify ways to allocate funds to priority programs." Reesema thinks that pharmaceutical companies will have to comply with the state's updated purchasing model, thus enabling payers to negotiate drug pricing based on health outcomes rather than models that are based purely on volume.

On the other hand, some specialists are concerned about the fact that managed care plans will no longer have complete control over their drug formularies. This could result in denied prescriptions and could greatly impact patient and provider satisfaction.

Dr. Adam Fein from Pembroke Consulting is unconvinced by the governor's order. Fein says, "It sounds like a supplemental rebate play. States can negotiate supplemental rebates with manufacturers (either through state pools or via managed care). Nearly all states already do this as single states or as part of a multistate group."

Sandeep Wadhwa, MD, chief health officer and senior vice president of government programs at Solera Health, agrees with Fein's observation. According to Wadhwa, "This is a bit like other state-administered services such as long-term services or dental care which may not be part of managed care contract. This will almost certainly require a state plan amendment to be approved by feds."

Read more here.

[pharmaphorumuk]

Prescient Intelligence & Insight Announces Recent Appointments to the Senior Team

Prescient hires three new senior members to strengthen and grow its Intelligence & Insight business

LONDON, July 15, 2020—Prescient, a biopharma product and portfolio strategy partner, announces the recent appointment of three new senior members to its Intelligence & Insight business: Dr. Anuj Gupta, Rob Littlefield and Dr. Emmanuel Reyes-Cortes. They join the existing Intelligence & Insight team shaping the competitive strategy of Prescient’s clients through enhanced decision support.

Anuj joins Prescient after several years in leadership roles across several advisory firms. He has a Bachelor’s degree in dental surgery and Master’s degree in business administration. Prior to joining Prescient, he helped global pharmaceutical companies launch drugs, define pricing strategies, optimize supply and distribution chains, and re-engineer DTC campaigns and patient engagement strategies. He has authored multiple articles in reputed publications and has been featured in industry debates on leading television networks. At Prescient, Anuj will lead our client engagements by leveraging his broad experience and strategic mindset.

Rob joins Prescient after more than 10 years of biopharmaceutical commercial strategy, market insights, data and analytics, business reporting and competitive intelligence experience. He earned his MSc in biomedical engineering from Columbia University and his BASc in biomedical engineering from Bucknell University. Prior to joining Prescient, he drove the new drug selection process and market review at Juniper Pharma and led enterprise information management and analytics at Intarcia Therapeutics. His pharma market analysis has been featured in The New York Times, The Wall Street Journal, Forbes and Thomson Reuters. At Prescient, Rob will leverage his oncology, women’s health, rare diseases and diabetes expertise to lead client projects, expand our Boston presence and support professional development among the team.

Emmanuel joins Prescient after spending several years supporting preclinical and clinical research as a trial manager in both large US medical systems and within the biopharmaceutical industry. He also co-founded a consulting firm to help integrate the use of technology into the practice of medicine. He holds an MD from the University of Cincinnati College of Medicine and an MSc in immunology from the Medical University of South Carolina. At Prescient, Emmanuel will deploy his clinical and research experience to support our hematology/oncology and infectious and rare disease clients as they navigate the complexities of bringing new therapies to patients in need.

“Our clients require a thought partnership built around disease area, functional and market expertise and the ability to deliver unrivalled competitive and market insight,” said Dr. Rakesh Verma, Prescient’s President. “Anuj, Rob and Emmanuel bring extensive industry, drug development and commercialization experience to help our clients in their endeavors to develop differentiated medicinal products which resonate with stakeholders.”

Biographies and contact information for the Prescient Intelligence & Insight team can be found on www.PrescientHG.com.

  About Prescient

At Prescient, science is at the core of everything we do. We are a biopharma product and portfolio strategy partner that specializes in turning the science of molecules into optimal patient outcomes and client value. Across therapeutic areas, we help develop winning strategies. When companies partner with us, a molecule in their hands has greater potential for success than the same science in the hands of their competitors.

Prescient Intelligence & Insight, a Prescient Healthcare Group business, offers best-in-class biopharmaceutical intelligence by providing impactful insight and decision support to product and portfolio teams from early clinical development through to loss of exclusivity.

Prescient has been a portfolio company of Baird Capital since 2017. For more information, please visit: www.PrescientHG.com.

The post Prescient Intelligence & Insight Announces Recent Appointments to the Senior Team appeared first on .

from https://pharmaphorum.com/partner-content/prescient-intelligence-insight-announces-recent-appointments-to-the-senior-team-2/

[variationsolution]

Variation Compusolution

Building organizations through improving careers is perhaps the most recommended way to hunt for a talent in the jobs industry. As a preferred talent acquisition partner for multinationals, Variation Compusolution is the most trusted recruitment consultants for leading businesses.

In more than two decades since our launch, we have received immense love and support for being the pioneer of organized recruitment and a market leader with unparalleled network of clients and job seekers. Our founder and CEO, Mandeep Kaur Ghotra, has always believed in helping companies grow, with the right talent. With a deep understanding and a rich experience in talent acquisition, Mandeep has bagged many awards in a Leadership role, few being…

-          Excellence award from Vikram Oberoi, MD, The Oberoi Group.

-          Business Leadership award at the India International Business Summit, New Delhi.

-          Best performer award, Bill Marriott.

-          Consistent performer award from Infosys, Chandigarh.

Her experience in talent acquisition taught Mandeep that not all industries are the same, which is why their needs for filling a job position will be different. And that is where the creative process for finding the best solution for problems in hiring began. As a firm, Variation Compusolution provides customized recruitment solutions for every need, pertaining to different industries it serves, few of them being Aviation and Aerospace, Chemical, Mining and Metals, Oil and Refinery, Pharma and Research, and Hospital and Healthcare.

With a skilled team of recruiting consultants, Variation Compusolution follows a very streamlined process of staffing, to provide the business, institution or a recruitment firm with the best talent. We understand that as the employer, a firm also puts in a lot of effort, time and money to train and induct a new employee as a part of the team. That is why our customized solutions are not only aimed at staff hunting, but also sustaining the satisfaction of our clients through our service and result-delivery timeline.    

[nathanstalbot]

Latest challenges in pharmaceutical trade

Doors open to the SMi’s 12th annual Parallel Trade Conference in just three weeks’ time. Don’t miss the opportunity to network with the industry’s leading parallel trade experts and discuss the latest challenges in pharmaceutical trade at the ONLY event of its kind!Doors open to the 12th annual Parallel Trade in just three weeks’ time. Don’t miss the opportunity to network with the industry’s leading parallel trade experts and discuss the latest challenges in pharmaceutical trade at the ONLY event of its kind!

Delegates confirmed:

ABACUS MEDICINE | Amgen | Apotek Hjärtat | Bayer | Boehringer Ingelheim | Bristol Myers Squibb | British Association of European Pharmaceutical Distributors | Celgene | International Clinical Insights | Covington & Burling | Danish Competition and Consumer Authority | Eli Lilly | Epilepsy Action | European Association of Euro-Pharmaceutical Companies | Ferring Pharmaceuticals | Gilead Sciences UK & Ireland | HOLLISTER | Intellectual Property Office | IQVIA | Irish Pharmacy Union | Kantar Health | Lexano | MD Pharma SA | Medac GmbH | Merck Romania | MHRA | Noehrenberg International Policy Consulting | Novartis Pharmaceuticals UK Ltd | Novo Nordisk |  Bioindustrie Sa | Roche | SANOFI | Sanofi Genzyme | Shire | TEVA  | Pharmachemie | The Economist Intelligence Unit

Over two days, parallel trade specialists will provide you with current, essential information on key issues surrounding the pharmaceutical parallel trade market, including:

– EVOLUTION OF PARALLEL TRADE IN PHARMA 4.0 Fabrizio Gianfrate, Professor of Health Economics, University of Ferrara – PARALLEL TRADE AND ANTITRUST – AN OVERVIEW OF RECENT DEVELOPMENTS IN THE EU Werner Berg, Partner, Baker & Mckenzie – DOES IT ALWAYS HAVE TO BE A FIGHT? CAN PARALLEL DISTRIBUTION AND INDUSTRY WORK TOGETHER? Antonio Mendonca Alves, CEO, MD Pharma SA – MARKET ACCESS POST BREXIT Felipe Florez-Arango, Head of Finance, Europe, Shire

Visit our website to view the programme and book your place www.parallel-trade.com/phphorum

CONTACT US: To sponsor or exhibit, contact Alia Malick on +44 (0)20 7827 6168For delegate and group bookings contact Fateja Begum on +44 (0)20 7827 6184

The post Latest challenges in pharmaceutical trade appeared first on Pharmaphorum.

from Pharmaphorum https://pharmaphorum.com/partner-content/latest-challenges-pharmaceutical-trade/ from HealthReviewsAndViews via Nathan Talbot on Inoreader https://pharmaphorumuk.tumblr.com/post/169830916020

[chawsl]

https://www.thedesertreview.com/opinion/letters_to_editor/ivermectin-wins-in-court-again-for-human-rights/article_98d26958-a13a-11eb-a698-37c06f632875.html

Ivermectin Wins in Court Again: For Human Rights

By Justus R. Hope, MD

 

Apr 19, 2021 Updated Apr 21, 2021

 

One dose of Ivermectin was all it took to get 81-year-old John Swanson off the ventilator. John’s wife Sandra could not believe it. His story is remarkably similar to other cases of patients who were on their way out with advanced COVID-19 but saved when Ivermectin was added.

Ralph Lorigo is the lawyer who now has won three court orders forcing New York hospitals to administer Ivermectin to dying patients. Incredibly, these three hospitals and their lawyers fought against the patients, arguing they did not have the right to receive the drug despite a valid prescription written by their doctors. In essence, the argument was that they did not have the right to try a potentially life-saving medication.

In each of the three cases, the New York State Supreme Court Justices sided with the patient, and in each of the three cases, the patients made near-miraculous recoveries after the Ivermectin was given. In each case, these patients were in the Intensive Care Unit on ventilators, unable to breathe on their own, and universally, after the drug was given, they rapidly improved and were able to breathe on their own.

Judith Smentkiewicz made national news in January when her family hired Lorigo after the hospital refused a fourth dose of Ivermectin. Smentkiewicz's son and daughter called Ivermectin a "miracle drug" in court papers. Attorney Lorigo and his associate Jon F. Minear reported, “This lady was on a ventilator, literally on her deathbed, before she was given this drug. As far as we’re concerned, the judge’s order saved this woman’s life.”

The family of Glenna "Sue" Dickinson happened to see a newspaper article of Judith's remarkable story, and they decided to try Ivermectin as well. 

Sue Dickinson, 65, contracted COVID-19 on January 7, 2021. She suffered progressive worsening and was admitted to Rochester General Hospital on January 12. She continued to worsen and was placed on a ventilator on January 17. The hospital staff advised that her chances of survival were about 40 percent.

With nothing to lose, Natalie Kingdollar, Dickinson’s daughter, reached out to their family doctor, Tom Madejski, who wrote the prescription. The hospital refused to give Sue the Ivermectin. The legal team of Lorigo and Minear drafted an affidavit from Dr. Madejski and sought an injunction. State Supreme Court Justice Frank Caruso ordered the hospital to provide the Ivermectin.

Dickinson, like Swanson, and Smentkiewicz, came off the ventilator and improved as well. The family reported on Facebook that, "She’s making progress each day, and it’s Ivermectin and God making this happen.” She has since been released from the hospital.

Ivermectin is widely used by physicians, as there are now 51 studies from around the world, with 50 showing clear benefit and one showing neutral. However, the lone study showing a neutral effect was roundly criticized as flawed in an open letter signed by a group of 120 physicians. 

Experts worldwide have called for the global and systematic use of Ivermectin to prevent and treat COVID-19. Physicians have recently written about a profit motive by regulatory agencies and Big Pharma to block cheap, safe, and effective treatments like Ivermectin and HCQ in favor of experimental and perhaps more dangerous and arguably less effective vaccines and medicines like Remdesivir. With *Remdesivir costing $3,100 per dose* and not reducing deaths, the choice of Ivermectin is a no-brainer say many doctors.

*Ivermectin costs about $2 per dose*. It is safer than Tylenol or most vitamins, says Dr. Pierre Kory of the FLCCC Alliance, a group of expert physicians promoting access and information through a nonprofit organization. Dr. Kory and Mr. Lorigo have teamed up to help other hospitalized patients gain access to the life-saving drug.

Dr. Fred Wagshul, a Yale-educated physician, is a pulmonary specialist and directs the Lung Center of America. He is also a founding member of the FLCCC Alliance. Dr. Wagshul notes that the typical dose for hospitalized patients is 0.3 mg of Ivermectin per kg of body weight for four days which works out to nine 3 mg tablets daily for four days in a typical 200-pound patient. 

Dr. George Fareed, former Harvard professor, advocates combination therapy of Ivermectin with HCQ in outpatient cases. For the benefit of physician readers, the specific doses are provided in this link.

The big problem is that information promoting Ivermectin is often censored or silenced as quickly as it is provided. Facebook, Reddit, Change.org, YouTube, and others have recently taken down posts on Ivermectin citing violation of "community standards." 

Physicians who employ good judgment and scientific studies are considered violators, as well as those who publish factual accounts of Ivermectin-based recovery stories. A recent article exposed the link between large pharmaceutical corporations and government regulatory agencies who have financial entanglements and massive conflicts of interest.

The disinformation campaign is evident with the publication of articles attempting to cast Ivermectin in a false light, referring to it as an “animal dewormer” that might be a “bad idea” for humans to use. In reality, many drugs are common to both humans and animals for treatment, including antibiotics, antifungals, and antiparasitic agents.

Ampicillin, a form of penicillin, has been widely used to treat infections in children like whooping cough, salmonella, and meningitis. It has been routinely used to treat adults for bronchitis, pneumonia, and rheumatic heart disease. It is also consistently employed in veterinary applications to treat calves, cattle, dogs, and cats.

You would never see an article attempting to smear Ampicillin as an animal drug and warn people against taking it. However, we see this propaganda daily trying to influence the general public against Ivermectin, a life-saving drug that has been prescribed safely and in billions of doses over the past 40 years for parasitic disease.

Dr. Satoshi Omura won the 2015 Nobel Prize in Medicine for his discoveries leading to the development of Ivermectin. In his praise for Ivermectin and its potential to help in the COVID-19 pandemic, Dr. Omura recently compared Ivermectin to Penicillin, “one of the greatest discoveries of the twentieth century.”

Currently, Ivermectin has already been adopted by 25 percent of the world’s countries to prevent and treat COVID-19. Bangladesh, where Ivermectin is broadly used in almost every home, enjoys a 99% lower per capita death rate from COVID-19 than the US. Bangladesh, with 160 million inhabitants, has half the US population. However, it has merely 10,000 COVID-19 deaths. Contrast that with nearly 580,000 US deaths in our country of 327 million. 

However, censorship, corruption, hospital lawyers, and disinformation campaigns have continued to stand in the way of its widespread acceptance in the United States. Many have never even heard of it.

Ivermectin recently won in court in South Africa after a protracted legal battle. Ralph Lorigo has now won his third State Supreme Court Injunction in New York. Will legal strategies also be required in the US to gain FDA approval for Ivermectin to treat COVID-19? 

Dr. Tess Lawrie has entered this David v. Goliath battle. She is an independent research consultant to the WHO, and her work has consistently been used to underpin International Clinic Practice Guidelines. In other words, she has been one of the go-to scientists on which the WHO bases their recommendations. 

She has established a non-profit organization to promote the worldwide approval and adoption of Ivermectin for COVID-19. She is requesting support through this video. 

We owe it to ourselves as human beings to support this work. We owe it to future generations who need medical truth, not corruption, to guide our public health policy. We owe it to the principle of basic human rights. 

Signed,

Justus R. Hope, MD